Andrey Pavlov, MD
Critical Care Medicine · Springfield, MANPI 1174818520
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.9% of the total across 112 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by GSK at 41.1% of the total.
Across 112 payments — averaging $17.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$787
- AstraZeneca$314
- Boehringer Ingelheim$199
- Amgen$142
- Insmed, Inc.$93
- Resmed Corp$66
- plus $316 from 8 others
What the payments were for
- Food & beverage$1,81995%
- Education$975%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 63 | $787 |
| AstraZeneca | 12 | $314 |
| Boehringer Ingelheim | 9 | $199 |
| Amgen | 6 | $142 |
| Insmed, Inc. | 5 | $93 |
| Resmed Corp | 1 | $66 |
| Regeneron Healthcare Solutions, Inc. | 3 | $62 |
| Novartis | 4 | $58 |
| Philips North America LLC | 2 | $49 |
| Genentech USA, Inc. | 2 | $40 |
| Sanofi | 2 | $39 |
| Baxter Healthcare | 1 | $25 |
| Verona Pharma, Inc. | 1 | $24 |
| Grifols USA, LLC | 1 | $20 |
How this compares
$1,916 in reported general payments places this provider in the 80th percentile of 158 critical care medicine providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 361 | $256,138 |
| Dupixent PenDupilumab | 69 | $252,867 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 279 | $138,114 |
| XolairOmalizumab | 49 | $134,644 |
| Breo ElliptaFluticasone/Vilanterol | 258 | $112,669 |
| Dupixent SyringeDupilumab | 21 | $75,048 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 69 | $45,513 |
| NucalaMepolizumab | 11 | $40,686 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 56 | $28,456 |
| Advair HfaFluticasone Propion/Salmeterol | 70 | $26,165 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 44 | $22,695 |
| Incruse ElliptaUmeclidinium Bromide | 60 | $20,497 |
| Spiriva RespimatTiotropium Bromide | 28 | $19,819 |
| Spiriva HandihalerTiotropium Bromide | 33 | $16,297 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 53 | $11,018 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Nucala, Incruse Ellipta | $787 | $574,848997 claims |
| Boehringer IngelheimStiolto Respimat, Combivent Respimat, Spiriva Respimat | $199 | $70,970128 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $314 | $55,015112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 158 critical care medicine providers in Massachusetts.
Other critical care medicine in Springfield
- Mark TidswellSpringfield$135K
- William McGeeSpringfield$32K
- Richard JudaSpringfield$1K
- Joshua AllgaierSpringfield$665
- Richard ChannickBoston$638K
- Ioana PrestonBurlington$544K
- Benjamin MedoffBoston$98K
- Jerome CrowleyBoston$38K
- Diana Espinoza BarreraBoston$17K
- Raghu SeethalaWeymouth$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.